ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
The snow falls and the calendar flips to 2026. The Memphis Grizzlies have churned out some incredible draft picks. We ...
Bryan will discuss our financial results at a strategic level, provide some further comments on our forward view of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback